NOSIP

Across TCGA pan-cancer cohorts, NOSIP mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NOSIP data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NOSIP mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NOSIP expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where NOSIP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.909	0.578	<.001	58	view →
HNSC	DFS	Quartile	IV	0.722	1.000	.001	20	view →
PDAC	DFS	Median	All	0.898	0.695	<.001	8	view →
LSCC	DFS	Tertile	All	0.860	0.246	.006	5	view →
GBM	OS	Quartile	All	0.609	0.292	.016	4	view →
CCRCC	OS	Quartile	All	0.855	1.000	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NOSIP–LUAD (OS)

Open the LUAD breakdown →